However, placebo-controlled randomised trials of CETP inhibitors did not show clear differences in infection rates between arms, despite increases in HDL in the treatment arm [22–24]; that said, these studies were not powered at or aimed to examine risk infection. The gene discussed is CETP; the disease is infection.